2015
DOI: 10.1016/j.chembiol.2015.10.011
|View full text |Cite
|
Sign up to set email alerts
|

Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G

Abstract: Summary ERβ is regarded as a “tumor suppressor” in breast cancer due to its anti-proliferative effects. However, unlike ERα, ERβ has not been developed as a therapeutic target in breast cancer due to loss of ERβ in aggressive cancers. In a small molecule library screen for ERβ stabilizers, we identified Diptoindonesin G (Dip G) which significantly increases ERβ protein stability, while decreasing ERα protein levesl. Dip G enhances the transcription and anti-proliferative activities of ERβ, while attenuating th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
29
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 34 publications
(33 citation statements)
references
References 68 publications
4
29
0
Order By: Relevance
“…These correlations are in line with the previous studies indicating that PR is a typical estrogen dependent target gene which is positively regulated by ERα and negatively regulated by ERβ 41 , 42 . Furthermore, ERα and ERβ expression levels were reversely regulated by several mechanisms such as proteasome pathway 43 , 44 and some microRNAs 45 , 46 . As for ERα36, EGFR and HER2, there was a significant positive correlation between ERα36, EGFR and HER2 protein expression in PTCs.…”
Section: Discussionmentioning
confidence: 99%
“…These correlations are in line with the previous studies indicating that PR is a typical estrogen dependent target gene which is positively regulated by ERα and negatively regulated by ERβ 41 , 42 . Furthermore, ERα and ERβ expression levels were reversely regulated by several mechanisms such as proteasome pathway 43 , 44 and some microRNAs 45 , 46 . As for ERα36, EGFR and HER2, there was a significant positive correlation between ERα36, EGFR and HER2 protein expression in PTCs.…”
Section: Discussionmentioning
confidence: 99%
“…With improved oral bioavailability, this compound shows promising preclinical results in mice (1214) and is now in Phase I clinical trials. Other compounds with oral bioavailability and high potency have also been described by AstraZeneca (1519), Pfizer (20), and other research groups (21). …”
Section: Selective Estrogen Receptor Downregulatorsmentioning
confidence: 95%
“…Although generated by individual genes, ERα and ERβ have almost 100% amino acid homology in their DNA-binding domain and about 60% amino acid homology in their protein-interacting domains [56]. Interestingly, in vivo and in vitro experiments demonstrated differential or opposite effects of ERα and ERβ on biological features of breast cancer cells [57]. ERα-regulated gene expressions facilitate the growth and survival of breast cancer cells in response to estrogens [58], whereas the impact of ERβ on breast cancer cells is controversial [59].…”
Section: Impacts Of Alternative Splicing Events On Apoptosismentioning
confidence: 99%